TARGINACT

This brand name is authorized in Croatia, Cyprus, Ecuador, Estonia, Netherlands, South Africa, UK.

Active ingredients

The drug TARGINACT contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII C1ENJ2TE6C - OXYCODONE HYDROCHLORIDE
 

Oxycodone is a full opioid agonist with no antagonist properties. It has an affinity for kappa, mu and delta opioid receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. The therapeutic effect is mainly analgesic, anxiolytic, antitussive and sedative.

 
Read more about Oxycodone
2
UNII F850569PQR - NALOXONE HYDROCHLORIDE
 

Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine.

 
Read more about Naloxone

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 TARGINACT Prolonged-release tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TARGINACT Prolonged release tablet MPI, Generic Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
N02AA55 Oxycodone and naloxone N Nervous system → N02 Analgesics → N02A Opioids → N02AA Natural opium alkaloids
Discover more medicines within N02AA55

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 5316-MEE-0720
EE Ravimiamet 1474275, 1474286, 1474297, 1474309, 1474310, 1474321, 1474332, 1474343, 1474354, 1474365, 1474433, 1474444, 1474455, 1474466, 1474477, 1474488, 1474499, 1474501, 1474512, 1474523, 1474635, 1474646, 1474657, 1474668, 1474679, 1474680, 1474691, 1474703, 1474714, 1474725, 1474736, 1474747, 1474758, 1474769, 1474770, 1474781, 1474792, 1474804, 1474815, 1474826, 1592276, 1592287, 1592298, 1592300, 1592311, 1592322, 1592333, 1592344, 1592355, 1592366, 1592377, 1592388, 1592399, 1592401, 1592412, 1592423, 1592434, 1592445, 1592456, 1592467, 1592535, 1592546, 1592557, 1592568, 1592579, 1592580, 1592591, 1592603, 1592614, 1592625, 1672523, 1672534, 1672545, 1672556, 1672567, 1672578, 1672589, 1672590, 1672602, 1672613, 1672624, 1672635, 1672646, 1672657, 1672668, 1672679, 1672680, 1672691, 1672703, 1672714
GB Medicines & Healthcare Products Regulatory Agency 149758, 149761, 158510, 158514, 373899, 373903, 373906, 373914, 377044, 377046, 377048, 377050, 381684, 381688, 381690, 381692
HR Agencija za lijekove i medicinske proizvode HR-H-347037202, HR-H-639349110, HR-H-875883221, HR-H-961831038
NL Z-Index G-Standaard, PRK 88838, 88846, 90220, 90239
ZA Health Products Regulatory Authority 46/2.9/0646, 46/2.9/0647, 46/2.9/0648

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.